https://scholars.lib.ntu.edu.tw/handle/123456789/189950
Title: | Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus | Authors: | CHIA-HSUIN CHANG JOU-WEI LIN Wu, Li-Chiu Lai, Mei-Shu LEE-MING CHUANG KIN-WEI CHAN |
Issue Date: | 2012 | Journal Volume: | 55 | Journal Issue: | 5 | Start page/Pages: | 1462-1472 | Source: | Hepatology | Abstract: | The objective of this nationwide case-control study was to evaluate the risk of specific malignancy in diabetic patients who received thiazolidinediones (TZDs). A total of 606,583 type 2 diabetic patients, age 30 years and above, without a history of cancer were identified from the Taiwan National Health Insurance claims database during the period between January 1 2000 and December 31 2000. As of December 31 2007, patients with incident cancer of liver, colorectal, lung, and urinary bladder were included as cases and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the odds ratio (OR) and 95% confidence interval (CI) between TZDs and cancer incidence. A total of 10,741 liver cancer cases, 7,200 colorectal cancer cases, and 70,559 diabetic controls were included. A significantly lower risk of liver cancer incidence was found for any use of rosiglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitazone (OR: 0.83, 95% CI: 0.72-0.95), respectively. The protective effects were stronger for higher cumulative dosage and longer duration. For colorectal cancer, rosiglitazone, but not pioglitazone, was associated with a significantly reduced risk (OR: 0.86; 95% CI: 0.76-0.96). TZDs were not associated with lung and bladder cancer incidence, although a potential increased risk for bladder cancer with pioglitazone use =3 years could not be excluded (OR: 1.56; 95% CI: 0.51-4.74). Conclusion: The use of pioglitazone and rosiglitazone is associated with a decreased liver cancer incidence in diabetic patients. The effects on occurrence of specific cancer types may be different for pioglitazone and rosiglitazone. (HEPATOLOGY 2012;) |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/258827 http://ntur.lib.ntu.edu.tw/bitstream/246246/258827/1/index.html |
DOI: | 10.1002/hep.25509 | SDG/Keyword: | insulin; metformin; oral antidiabetic agent; pioglitazone; rosiglitazone; sulfonylurea; adult; aged; article; bladder cancer; cancer incidence; cancer risk; case control study; colorectal cancer; controlled study; disease association; female; human; liver cancer; lung cancer; major clinical study; male; non insulin dependent diabetes mellitus; priority journal; side effect; Taiwan; treatment duration; Administration, Oral; Adult; Age Distribution; Case-Control Studies; Colorectal Neoplasms; Confidence Intervals; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Middle Aged; Odds Ratio; Prevalence; Risk Assessment; Severity of Illness Index; Sex Distribution; Survival Analysis; Taiwan; Thiazolidinediones |
Appears in Collections: | 醫學系 |
File | Description | Size | Format | |
---|---|---|---|---|
index.html | 23.15 kB | HTML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.